Skip to content

Effect of Mango Consumption on Individuals with Pre-diabetes

The Effects of Fresh Mango Consumption in Indices of Glycemic Control, Cardiovascular Health, and Body Composition in Normal Weight, Overweight and Obese Individuals with Prediabetes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05571800
Enrollment
24
Registered
2022-10-07
Start date
2022-05-01
Completion date
2024-07-31
Last updated
2024-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PreDiabetes, Obesity

Keywords

Glycemic Control, Cardiovascular Health, Overweight, Obese, Glycemic Indices, Body Composition

Brief summary

This study is designed to explore the effect of mango consumption on glycemic indices, cardiovascular health, and body composition in overweight and obese individuals with prediabetes.

Detailed description

According to the Centers for Disease Control and Prevention (2016), at least 100 million adults in the United States are diagnosed as pre-diabetic or Type 2 diabetic. With the number of cases steadily increasing in this population, healthcare costs have subsequently increased for both the patient and the health care system. To date, there are few studies (limited to animal model and obese Type 2 diabetic humans) that have examined the efficacy of mangoes on health outcomes, particularly related to diabetes. Therefore, the purpose of the current study is to examine the effect of fresh mango on glycemic indices, body composition, and vascular health measures. Upon favorable outcomes, and with more definite evidence from human studies, mangoes can potentially be implemented in America's diet to help mitigate the advancement and diagnoses of pre and Type 2 diabetes and, as a result, aid in a reduction of healthcare costs. The current study is a 24- week, randomized, controlled experiment including 40 overweight or obese, pre-diabetic men and post-menopausal women aged 50 to 70 years with no diagnosed cardiovascular, metabolic, kidney, or other types of chronic disease to be included. Participants will be randomly assigned to one of two groups: 1) one fresh Tommy Atkins mango (120 g) per day or 2) an isocaloric granola bar per day for 24 weeks. Visits will include anthropometric measurements, glucose, and A1C values via finger prick, venous blood samples to analyze biomarkers related to glycemic control and lipid profiles, vascular measures, and body composition. To analyze the effects of the treatment, ANOVA and Bonferroni's test will be utilized. The investigators hypothesize that daily consumption of one mango per day for 24 weeks will improve the indices of glycemic control, cardiovascular health, and body composition in overweight and obese individuals with prediabetes.

Interventions

OTHERMango

120g of fresh Mango

OTHERPlacebo

200g isocaloric Granola Bar

Sponsors

National Mango Board
CollaboratorOTHER
Florida State University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Masking description

None (Open Label)

Intervention model description

Randomized, calorie-match controlled

Eligibility

Sex/Gender
ALL
Age
50 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Free of any chronic diseases such as cancer * BMI of 18.5 kg/m2 to 34.9 kg/m2 * wHbA1c values are 100 mg/dl to 125 mg/dl and HbA1C of 5.7-6.4 %

Exclusion criteria

* Individuals diagnosed with cardiovascular diseases (CVD), type 2-diabetes, type 1 diabetes mellitus, other active chronic diseases such as cancer, asthma, glaucoma, kidney, liver and pancreatic disease * Uncontrolled hypertension (≥160/100 mmHg) * BMI \<18.5 kg/m2 or \>34.9 kg/m2 * Not post-menopausal or have been taking hormone replacement therapy for less than 3 months * taking more than one anti-hypertensive or have been taking them for less than 3 months * Participating in a weight loss program or having lost or gain ≥10% bodyweight within the last 6 months * Smoke more than 1 pack/day * Consumption of \>12 alcoholic drinks/week * Frequent mango consumers (\>5 servings/2weeks) * In concurrent participation with another investigational study * Currently consuming any performance supplement (i.e. creatine, nitric oxide, whey/casein protein, branched chain amino acids). * None of the following special populations will be included: adults unable to consent, individuals who are not yet adults (infants, children, teenagers), pregnant women, or prisoners.

Design outcomes

Primary

MeasureTime frameDescription
Effect of mango consumption on glycemic control using blood glucose measures3 yearsBlood glucose measures evaluated with finger prick and blood glucose meter
Effect of mango consumption on glycemic control using HbA1c3 yearsHbA1c evaluated by finger prick and DCA analyzer
Effect of mango consumption on glycemic control evaluated by Insulin3 yearsInsulin evaluated by blood draw Enzyme-linked immunosorbent assay
Effect of mango consumption on glycemic control evaluated by HOMA-IR3 yearsHOMA-IR evaluated by blood draw 20 ml Enzyme-linked immunosorbent assay
Effect of mango consumption on glycemic control evaluated by HOMA-β3 yearsHOMA-β evaluated by blood draw 20 ml and Enzyme-linked immunosorbent assay

Secondary

MeasureTime frameDescription
Effect of mango consumption on indicators of cardiovascular health evaluated by lipid profile3 yearslipid profile evaluated by blood draw and enzyme-linked immunosorbent assay consisting of * Triglycerides (TG) * Total cholesterol (TC) * Low-density lipoprotein cholesterol (LDL-C) * Oxidized LDL (Ox-LDL) * High-density lipoprotein cholesterol (HDL-C)
Atherogenic risk ratio (TC/HDL-C, LDLC/HDL-C, HDL-C/LDL-C)3 yearsEffect of mango consumption on indicators of cardiovascular health evaluated by lipid profile
Effect of mango consumption on body composition evaluated by lean mass3 yearsLean mass evaluated by bioimpedance spectroscopy (BIS)
Effect of mango consumption on body composition evaluated by fat mass3 yearsfat mass evaluated by bioimpedance spectroscopy (BIS)
Effect of mango consumption on indicators of cardiovascular health evaluated by systolic and diastolic blood pressure3 yearsSystolic and diastolic blood pressure evaluated by automated blood pressure monitor
Effect of mango consumption on body composition evaluated by weight3 yearsWeight evaluated by Ohaus Portable Electronic CS Series Scales
Effect of mango consumption on anthropometric measure of Waist circumference (WC)3 yearsevaluated by Gulick fiberglass measuring tape with a tension handle
Effect of mango consumption on anthropometric measure of HC3 yearship circumference (HC) evaluated by Gulick fiberglass measuring tape with a tension handle
Effect of mango consumption on anthropometric measure WC/HC ratio3 yearswaist to hip ratio (WC/HC)
Effect of mango consumption on body composition evaluated by phase angle (PA)3 yearsPhase angle (PA) calculated directly from reactance and resistance using the following formula: PA=arctangent reactance(ohm)/resistance (ohm) ×180°/π
Effect of mango consumption on indicators of cardiovascular health evaluated by Indirect bioassay of in vivo endothelial function with FMD3 yearsFlow-mediated dilation (FMD) evaluated with high-resolution doppler ultrasound (HD11XE, Phillips Ultrasound, Bothwell, WA, USA) with a 3-12 MHz linear array transducer
Effect of mango consumption on indicators of cardiovascular health evaluated by Indirect bioassay of in vivo endothelial function with PWV3 yearsPulse wave velocity (PWV) evaluated with Sphygmocor for pulse wave velocity, aortic blood pressure and augmentation index
Effect of mango consumption on indicators of cardiovascular health evaluated by Indirect bioassay of in vivo endothelial function with ET-13 yearsEndothelin-1 (ET-1) evaluated with Enzyme-linked immunosorbent assay
Effect of mango consumption on indicators of cardiovascular health evaluated by biomarker of inflammation (C-reactive protein)3 yearsbiomarker of inflammation (C-reactive protein) evaluated by blood draw 20 ml and enzyme-linked immunosorbent assay

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026